

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group To Be Assigned 1644

U.S. PATENT DOCUMENTS							
Examiner Initials	*	Document Number	Date	Name	Class	Subclass	Filing Date
<div style="position: relative; height: 100%;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; transform: rotate(-90deg); transform-origin: left top; pointer-events: none;"> RECEIVED T-08 CENTER 1500/2500 02 APR 18 PM 12:50 </div> </div>		1 08/508,014		Fick et al.			27.07.95
	*	2 4,093,606	06.06.78	Coval, M.			
	*	3 4,499,073	12.02.85	Tenold, R.			
		4 4,714,759	22.12.87	Whitaker, Jr.			
		5 4,816,567	28.03.89	Cabilly et al.			
		6 4,861,579	29.08.89	Meyer et al.			
	*	7 4,877,608	31.10.89	Lee, T. et al.			
	*	8 4,891,319	02.01.90	Roser			
	*	9 4,940,782	10.07.90	Rup et al.			
		10 4,946,788	07.08.90	Delespesse			
		11 4,962,035	09.10.90	Leder et al.			
	*	12 5,032,405	16.07.91	Huang, H. et al.			
	*	13 5,036,049	30.07.91	Audhya, T. et al.			
		14 5,091,313	25.02.92	Chang, T.			
	*	15 5,096,885	17.03.92	Pearlman et al.			
	*	16 5,149,653	22.09.92	Roser			
	*	17 5,215,743	01.06.93	Singh, M. et al.			
		18 5,231,026	27.07.93	Chang, T.			
		19 5,252,467	12.10.93	Chang, T.			
		20 5,254,671	19.10.93	Chang, T.			
		21 5,260,416	09.11.93	Chang, T.			
	*	22 5,262,296	16.11.93	Ogawa, E. et al.			
		23 5,274,075	28.12.93	Chang, T.			
		24 5,292,867	08.03.94	Chang, T.			
		25 5,342,924	30.08.94	Chang, T.			
		26 5,362,643	08.11.94	Chang, T.			
	*	27 5,399,670	21.03.95	Bhattacharya, P. et al.			
	*	28 5,410,025	25.04.95	Moller et al.			
		29 5,420,251	30.05.95	Chang et al.			
		30 5,422,258	06.06.95	Chang, T.			
		31 5,428,133	27.06.95	Chang, T.			
	*	32 5,514,554	07.05.96	Bacus, S.			
	*	33 5,571,894	05.11.96	Wels, W. et al.			
	*	34 5,580,856	03.12.96	Prestrelski et al.			
	*	35 5,587,458	24.12.96	King, C. et al.			
	*	36 5,589,167	31.12.96	Cleland et al.			

Examiner M. E. Gammon	Date Considered 5/9/02
------------------------------	-------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3		Serial No. 09/705,457	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.			
				Filing Date 02 Nov 2000	Group 1644 To Be Assigned		
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
MJ	* 37	5,608,038	04.03.97	Eibl et al.			
	* 38	5,725,856	10.03.98	Hudziak et al.			
	* 39	5,763,409	09.06.98	Bayol et al.			
	* 40	5,821,337	13.10.98	Carter et al.			
	* 41	5,849,700	15.12.98	Sorensen et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
MJ	* 42	AU-B-30771/89 ✓	07.09.89	AUSTRALIA			
	* 43	2,138,853 ✓	29.06.95	CANADA			
	* 44	0 531 539 A1 ✓	17.03.93	EPO			
NB	* 45	171,496 ✓	19.02.86	EPO			
	46	173,494	05.03.86	EPO			
	47	184,187	11.06.86	EPO			
	48	255,249	03.02.88	EPO			
	49	263,655	13.04.88	EPO			
MJ	* 50	303,746 ✓	22.02.89	EPO			
	51	317,295	24.05.89	EPO			
MJ	* 52	391,444 ✓	10.10.90	EPO			
	53	589,840	30.03.94	EPO			
MJ	* 54	597,101 ✓	18.05.94	EPO			
	55	617,127	28.09.94	EPO			
	56	648,499	19.04.95	EPO			
MJ	* 57	661,060 ✓	05.07.95	EPO (WITH ENGLISH ABSTRACT) Abstract only			X
	* 58	841,067 ✓	13.05.98	EPO			
	59	59-44399	12.03.84	JAPAN (TRANSLATION ATTACHED)			
DMS	* 60	WO 84/00890 ✓	15.03.84	PCT			
	61	WO 86/01533 ✓	13.03.86	PCT			
	62	WO 89/04834 ✓	01.06.89	PCT			
	63	WO 89/06138 ✓	13.07.89	PCT			
	64	WO 89/06692 ✓	27.07.89	PCT			
	* 65	WO 89/09402 ✓	05.10.89	PCT (WITH ENGLISH ABSTRACT) Abstract only			X
	* 66	WO 89/11297 ✓	30.11.89	PCT			
	* 67	WO 90/11091 ✓	04.10.90	PCT			
	68	WO 91/11456 ✓	08.08.91	PCT			
	* 69	WO 92/22653 ✓	23.12.92	PCT			
Examiner M.E. Oramo				Date Considered 5/9/02 & 7/9/02			
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457		
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.			
				Filing Date 02 Nov 2000	Group <u>1044</u> To Be Assigned		
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
MMS ↓	70	WO 93/04173	04.03.93	PCT			
	* 71	WO 93/05799	01.04.93	PCT			
	72	WO 93/19197	30.09.93	PCT			
	73	WO 95/15977	15.06.95	PCT			
	74	WO 97/04807	13.02.97	PCT			
	75	WO 97/10004	20.03.97	PCT			
	76	WO 97/33616	18.09.97	PCT			
	* 77	WO 98/22136	28.05.98	PCT <i>Abstract only</i>			
	78	WO 99/01556	14.01.99	PCT			X
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)							
MMS ↓	* 79	Arakawa et al., "Protein-Solvent Interactions in Pharmaceutical Formulations" <u>Pharmaceutical Research</u> 8(3):285-291 (1991)					
	* 80	Bam et al., "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique" <u>Pharm. Res.</u> 12:2-11 (1995)					
	81	Baniyash et al., "Anti-IgE monoclonal antibodies directed at the Fc _ε receptor binding site" <u>Molecular Immunology</u> 25(8):705-711 (1988)					
	82	Baniyash et al., "Inhibition of IgE Binding to Mast Cells and Basophils by Monoclonal Antibodies to Murine IgE" <u>European Journal of Immunology</u> 14:799-807 (1984)					
	* 83	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)					
	* 84	Beauvais et al., "Both Glassy State and Native Structure are Required for Storage Stability of Lyophilized Interleukin-1 Receptor Antagonist" <u>Pharm. Res.</u> (Abstract #2007) 12(9):S-80 (1995)					
	85	Berglund et al., "Spirometric studies in normal subjects" <u>Acta. Med. Scand.</u> 173:185-192 (1963)					
	86	Blank et al., "Characterization of Truncated α Chain Products from Human, Rat, and Mouse High Affinity Receptor for Immunoglobulin E" <u>Journal of Biological Chemistry</u> 266(4):2639-2646 (February 5, 1991)					
	* 87	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response" <u>Am J Respir Crit Care Med</u> 155:1835-1840 (1997)					
	88	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)					
	89	Bozelka et al., "Effects of Anti-ε on Total and Specific IgE Levels in Adult Mice" <u>Int. Archs. Allergy Appl. Immun.</u> 78:51-56 (1985)					
	90	Bozelka et al., "IgE isotype suppression in anti-ε-treated mice" <u>Immunology</u> 46:527-532 (1982)					
91	Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991)						
92	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)						
Examiner <u>M.E. Gammon</u>				Date Considered <u>5/9/02</u> & <u>7/9/02</u>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group <u>1644</u> To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
93	Burrows et al., "Association of asthma with serum IgE levels and skin-test reactivity to allergens" <u>New England J. of Medicine</u> 320(5):271-277 (Feb. 2, 1989)				
94	Burt et al., "Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies" <u>Molecular Immunology</u> 24(4):379-389 (1987)				
95	Burt et al., "Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides" <u>European Journal of Immunology</u> 17:437-440 (1987)				
* 96	Chang and Fischer, "Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations" <u>Pharm. Res.</u> 12(6):831-837 (1995)				
* 97	Chang et al., "Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist" <u>Pharmaceutical Research</u> 13(2):243-248 (1996)				
98	Chang et al., "Monoclonal Antibodies Specific for Human IgE-producing B Cells: A Potential Therapeutic for IgE-mediated Allergic Diseases" <u>Bio/Technology</u> 8:122-126 (February 1990)				
* 99	Cleland and Jones, "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:514-515 (1995)				
* 100	Cleland et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation" <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> 10(4):307-377 (1993)				
101	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)				
102	Cockcroft et al., "Allergen-induced increase in non-allergic bronchial reactivity" <u>Clinical Allergy</u> 7:503-513 (1977)				
103	Cockcroft et al., "Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine" <u>J. Allergy Clin. Immunol.</u> 79(5):734-740 (May 1987)				
104	Cockcroft et al., "Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine" <u>Am. Rev. Respir. Dis.</u> 135:264-267 (1987)				
105	Cockcroft et al., "rhuMAB-E25 (E25), Humanized Murine Monoclonal Anti-IgE, Inhibits the Allergen-induced Early Asthmatic Response (EAR)" <u>J. of Allergy and Clinical Immunology</u> (Abstract no. 532) 97(1 Part III):315 (January 1996)				
106	Cohn et al., "Induction of Airway Mucus Production By T Helper 2 (Th2) Cells: A Critical Role for Interleukin 4 In Cell Recruitment But Not Mucus Production" <u>Journal of Experimental Medicine</u> 186(10):1737-1747 (November 17, 1997)				
107	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York: Alan R. Liss, Inc. pps. 77-96 (1985)				
108	Conrad et al., "The Interaction of Human and Rodent IgE with the Human Basophil IgE Receptor" <u>J. of Immunology</u> 130(1):327-333 (1983)				
109	Conrad, D.H., "FcεRII/CD23: The low affinity receptor for IgE" <u>Ann. Rev. Immunol.</u> 8:623-639 (1990)				
110	Corrigan et al., "T Cells and Eosinophils in the Pathogenesis of Asthma" <u>Immunology Today</u> 13(12):501-507 (1992)				
111	Coyle et al., "Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody" <u>Journal of Experimental Medicine</u> 183:1303-1310 (April 1996)				
112	Crescioli et al., "Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects" <u>Ann. Allergy</u> 66:245-251 (March 1991)				
Examiner <u>M. E. Gorman</u>		Date Considered <u>5/9/02</u> <u>5/7/9/02</u>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group <u>144</u> To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<u>MS</u>	113	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991)			
	114	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc Fragment and its complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution" <u>Biochemistry</u> 20(9):2361-2370 (April 28, 1981)			
	115	Diaz et al., "Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions" <u>Am. Rev. Respir. Dis.</u> 139:1383-1389 (1989)			
	116	Dodge et al., "The prevalence and incidence of asthma and asthma-like symptoms in a general population sample" <u>Am. Rev. Respir. Dis.</u> 122:567-575 (1980)			
	*117	Draber et al., "Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose" <u>Journal of Immunological Methods</u> 181(1):37-43 (1995)			
	118	Duncan et al., "Localization of the binding site for the human high-affinity FC receptor on IgG" <u>Nature</u> 332:563-564 (April 7, 1988)			
	119	Fahy et al., "Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: A method for studying allergic airway inflammation" <u>J. Allergy Clin. Immunol.</u> 93(6):1031-1039 (June 1994)			
	120	Fahy et al., "Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects" <u>Am. Rev. Respir. Dis.</u> 147:1126-1131 (1993)			
	*121	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J Respir Crit Care Med</u> 155:1828-1834 (1997)			
	122	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
	123	Fick et al., "Bronchoalveolar Lavage in Allergic Asthmatics" <u>Am. Rev. Respir. Dis.</u> 135:1204-1209 (1987)			
	124	Fick et al., "Increased bronchovascular permeability after allergen exposure in sensitive asthmatics" <u>J. Appl. Physiol.</u> 63(3):1147-1155 (1987)			
	125	Fisher et al., "Biostatistics: a methodology for the health sciences", New York:John Wiley & Sons pps. 861-862 (1993)			
	126	Froehlich et al., "Multiple Doses of a Recombinant Humanized Monoclonal Anti IgE Antibody Are Safely Tolerated and Decrease Free Serum IgE to Undetectable Levels" <u>J. Allergy and Clinical Immunology</u> (Abstract #863) 95(1 Part II):356 (January 1995)			
	127	Geha et al., "IgE sites relevant for binding to type 1 Fc epsilon (FCER) receptors on mast cells" <u>J. Allergy & Clin. Immunol.</u> (Abstract No. 20) 79(1):129 (1987)			
	128	Glennie et al., "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'g Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987)			
	129	Gonzalez et al., "Allergen-Induced Recruitment of Bronchoalveolar Helper (OKT4) and Suppressor (OKT8) T-Cells in Asthma" <u>Am. Rev. Respir. Dis.</u> 136:600-604 (1987)			
	130	Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991)			
	131	Grammer et al., "Diagnosis and classification of asthma" <u>Chest</u> 101(6):393S-395S (June 1992)			
<u>✓</u>	132	Gundel et al., "Endothelial Leukocyte Adhesion Molecule-1 Mediates Antigen-Induced Acute Airway Inflammation and Late-Phase Airway Obstruction in Monkeys" <u>J. Clin. Invest.</u> 88:1407-1411 (October 1991)			
Examiner <u>M.E. Gammon</u>		Date Considered <u>5/9/02 & 7/9/02</u>			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM-PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group <u>164</u> To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
133	Haak-Frendscho et al., "Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo" <u>Immunology</u> 82:306-313 (1994)				
134	Hakimi et al., "The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)				
135	Hammerling et al., "Production of Antibody-Producing Hybridomas in the Rodent Systems" <u>Monoclonal Antibodies and T-Cell Hybridomas</u> , New York:Elsevier, Chapter 12, pps. 563-587 (1981)				
136	Hargreave, F.E., "Late-phase asthmatic responses and airway inflammation" <u>J. Allergy Clin. Immunol.</u> 83(2):525-527 (February 1989)				
137	Helm et al., "Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ϵ -chain fragment of 76 amino acids" <u>Proc. Natl. Acad. Sci.</u> 86:9465-9469 (December 1989)				
138	Helm et al., "The mast cell binding site on human immunoglobulin E" <u>Nature</u> 331:180-183 (January 14, 1988)				
139	Hoffman, D. R., "Enzyme-linked immunosorbent assays (ELISA) for immunoglobulin E and blocking antibodies" <u>Methods in Enzymology</u> , Chapter 45, 73:656-666 (1981)				
140	Hook et al., "Monoclonal Antibodies Defining Epitopes on Human IgE" <u>Molecular Immunology</u> 28(6):631-639 (1991)				
141	Hook et al., "Monoclonal antibodies defining epitopes on IgE" <u>Federation of American Societies for Experimental Biology</u> (71st Annual Meeting, Abstract #6008) pps. 1346 (1987)				
142	Hook et al., "Monoclonal antibodies to human IgE" <u>Federation Proceedings</u> (Abstract No. 4177 Only) 40(3):968 (1994)				
*143	"Immune Globulin Intravenous (Human) Sandoglobulin" <u>Product Information, Physicians' Desk Reference</u> pps. 2075-2077 (1994)				
144	Ishizaka, K., "Immunoglobulin E (IgE)" <u>Methods in Enzymology</u> 116(Part II):76-94 (1985)				
*145	"IVEEGAM", "Product Information, IMMUNO U.S., Inc." pps. 2 pages (1992)				
*146	Izutsu et al., "The effects of additives on the stability of freeze-dried β -galactosidase stored at elevated temperature" <u>Intl. J. Pharmaceutics</u> 71:137-146 (1991)				
147	Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986)				
148	Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFc γ R)" <u>Molecular Immunology</u> 27(12):1237-1240 (1990)				
149	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)				
150	Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990)				
151	Kabat <u>Sequences of Proteins of Immunological Interest</u> (pgs. 662-663, 671-672, 680-681, 697, 701-702, 710, 719-720, 2275-2276), 5th edition 1 (1991)				
152	Kabat <u>Sequences of Proteins of Immunological Interest</u> , 4th edition pps. 41-42, 167-168 (1987)				
Examiner <u>M.E. O'neal</u>		Date Considered <u>5/9/02</u> & <u>7/19/02</u>			
*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group <u>164</u> To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
153		Kay et al., "Mediators of Hypersensitivity and Inflammatory Cells in Early- and Late-Phase Asthmatic Reactions" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 13), Kay et al., New York:Academic Press pps. 211-227 (1984)			
154		Kohler et al., "Derivation of Specific Antibody-producing Tissue Culture and Tumor Lines by Cell Fusion" <u>European Journal of Immunology</u> 6:511-519 (1976)			
155		Korsgren et al., "Allergic Eosinophil-rich Inflammation Develops in Lungs and Airways of B Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 185(5):885-892 (March 1997)			
156		Kulczycki et al., "The Interaction of IgE with Rat Basophilic Leukemia Cells, Evidence for Specific Binding of IgE" <u>Journal of Experimental Medicine</u> 139:600-616 (1974)			
157		Kurokawa et al., "Expression of human immunoglobulin E ϵ chain cDNA in E. coli" <u>Nucleic Acids Research</u> 11(10):3077-3085 (1983)			
158		Larsen et al., "An Animal Model of the Late Asthmatic Response to Antigen Challenge" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 15), Kay et al., New York:Academic Press pps. 245-262 (1984)			
159		Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular & Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)			
160		Liu et al., "Expression of a biologically active fragment of human IgE ϵ chain in Escherichia coli" <u>Proc. Natl. Acad. Sci.</u> 81:5369-5373 (September 1984)			
*161		Manning et al., "Stability of Protein Pharmaceuticals" <u>Pharm. Res.</u> 6(11):903-918 (1989)			
162		Marsh et al., "Increases in Airway Reactivity to Histamine and Inflammatory Cells in Bronchoalveolar Lavage after the Late Asthmatic Response in an Animal Model" <u>Am. Rev. Respir. Dis.</u> 131:875-879 (1985)			
163		Metzger et al., "How Antibodies Work: Focus on Fc Receptors" <u>FASEB J.</u> 2(1):3-11 (January 1988)			
164		Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)			
165		Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)			
166		Murray et al., "Dust-Free Bedrooms in the Treatment of Asthmatic Children with House Dust or House Dust Mite Allergy: A Controlled Trial" <u>Pediatrics</u> 71(3):418-422 (March 1983)			
167		Nakajima et al., "CD4 ⁺ T-Lymphocytes and Interleukin-5 Mediate Antigen-induced Eosinophil Infiltration into the Mouse Trachea" <u>Am. Rev. Respir. Dis.</u> 146:374-377 (1992)			
168		Nakajima et al., "Effect of Saiboku-to (TJ-96) on Bronchial Asthma" <u>Annals of the New York Academy of Sciences</u> 685:549-560 (June 23, 1993)			
169		Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" <u>Nature</u> 314:268-270 (March 21, 1985)			
170		Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)			
171		Neurath, A. R., "Use of ¹²⁵ I-labeled anti-2,4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays" <u>Methods in Enzymology</u> 73:127-138 (1981)			
*172		Nielsen, et al., "Stability of Freeze Dried Horseradish Peroxidase Conjugated Monoclonal Antibodies Used in Diagnostic Serology" <u>Journal of Immunoassay</u> 16(2):183-197 (1995)			
Examiner <u>M. E. Januoy</u>				Date Considered <u>5/9/02</u> <u>5/7/02</u>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	
Group <u>1644</u> <u>To Be Assigned</u>					
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
173	Nio et al., "Inhibition of histamine release by synthetic human IgE peptide fragments: structure-activity studies" <u>Peptide Chemistry</u> pps. 203-208 (1989)				
174	Nissim et al., "Mapping of the high affinity Fcε receptor binding site to the third constant region domain of IgE" <u>EMBO Journal</u> 10(1):101-107 (Jan 1991)				
175	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990)				
176	Oi et al., "Chimeric Antibodies" <u>BioTechniques</u> 4(3):214-221 (1986)				
177	Padlan et al., "A model of the Fc of immunoglobulin E" <u>Molecular Immunology</u> 23(10):1063-1075 (1986)				
*178	Pearlman et al., "Analysis of Protein Drugs" <u>Peptide and Protein Drug Delivery</u> , Vincent H. L. Lee, Marcel Dekker, Inc., Chapter 6, pps. 247-301 (1991)				
*179	Pikal et al., "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone" <u>Pharm. Res.</u> 8:427-436 (1991)				
*180	Pikal, M., "Freeze-Drying of Proteins, Part 2: Formulation Selection" <u>Biopharm.</u> 3(9):26-30 (1990)				
181	Platts-Mills et al., "Reduction of Bronchial Hyperreactivity During Prolonged Allergen Avoidance" <u>Lancet</u> 2(8300):675-678 (September 25, 1982)				
*182	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)				
183	Qu et al., "Expression and Characterization of a Truncated Murine Fcγ Receptor" <u>Journal of Experimental Medicine</u> 167:1195-1210 (March 1988)				
184	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)				
185	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)				
186	Riske et al., "High Affinity Human IgE Receptor (FcεRI). Analysis of functional Domains of the α-Subunit with Monoclonal Antibodies" <u>Journal of Biological Chemistry</u> 266(17):11245-11251 (June 15, 1991)				
187	Robertson et al., "IgE structure-function relationships defined by sequence directed antibodies induced by synthetic peptides" <u>Molecular Immunology</u> 25(2):103-113 (1988)				
188	Rup et al., "Identification of a Mouse Anti-Rat IgE Monoclonal Antibody, 44.7b, Which Inhibits IgE Binding to RBL Cells" <u>International Archives of Allergy & Applied Immunology</u> 89(4):387-393 (1989)				
189	Saban et al., "Human FcεRI-IgG and Humanized Anti-IgE Monoclonal Antibody MaE11 Block Passive Sensitization of Human and Rhesus Monkey Lung" <u>J. Allergy and Clinical Immunology</u> 94(5):836-843 (November 1994)				
*190	"Sandoglobulin" <u>Physicians' Desk Reference</u> pps. 1965-1966 (1991)				
191	Schwarzbaum et al., "Mapping of murine IgE epitopes involved in IgE-Fcε receptor interactions" <u>European Journal of Immunology</u> 19:1015-1023 (1989)				
192	Shaw et al., "Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses" <u>J. Nat. Canc. Inst.</u> 80(19):1553-1559 (December 7, 1988)				
Examiner <u>M. E. Gamoy</u>		Date Considered <u>5/9/02 & 7/9/02</u>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group 164 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
193	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)				
194	"Standardization of Spirometry - 1987 Update" <u>Am. Rev. Respir. Dis.</u> (American Thoracic Society, Medical Section of the American Lung Association) 136:1285-1298 (1987)				
195	Stanworth et al., "Synthetic peptides comprising sequences of the human immunoglobulin E heavy chain capable of releasing histamine" <u>Biochemical Journal</u> 180(3):665-668 (1979)				
196	Stanworth et al., "The use of synthetic peptides in the delineation of immunoglobulin antigenic epitopes and Fc effector functions" <u>Symposium on Synthetic Peptides as Antigens</u> (Ciba Foundation symposium 119), New York:Wiley Vol. 119:226-244 (1986)				
197	Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" <u>Nature</u> 314(6010):452-454 (April 4, 1985)				
198	Takeda et al., "Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness in Mast Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 186(3):449-454 (August 1997)				
199	Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <u>Journal of Immunology</u> 143(8):2595-2601 (Oct 15, 1989)				
200	Tepper et al., "The Role of Mast Cells and IgE in Murine Asthma" <u>Asthma Theory to Treatment</u> (Abstract Only) pps. 8 (July 15, 1995)				
201	Tung, A. S., "Production, purification, and characterization of antigen-specific murine monoclonal antibodies of IgE class" <u>Methods in Enzymology</u> , Chapter 6, 92:47-66 (1983)				
202	Vercelli et al., "The B-cell binding site on human immunoglobulin E" <u>Nature</u> 338:649-651 (April 20, 1989)				
203	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)				
*204	Wang et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers" <u>J. Parenteral Sci. Tech.</u> (Technical Report No. 10) 42(2S):S4-S26 (1988)				
205	Ward et al., "Theophylline--an Immunomodulatory Role In Asthma?" <u>Am. Rev. Respir. Dis.</u> 147(3):518-523 (1993)				
206	Weetall et al., "Mapping the site of interaction between murine IgE and its high affinity receptor with chimeric Ig" <u>J. Immunol.</u> 145(11):3849-3854 (December 1, 1990)				
207	Weiss et al., "The Interrelationship Among Allergy, Airways Responsiveness, and Asthma" <u>J. Asthma</u> 30(5):329-349 (1993)				
208	Zweiman, B., "The Late-Phase Reaction: Role of IgE, Its Receptor and Cytokines" <u>Current Opinion in Immunology</u> 5:950-955 (1993)				
Examiner <u>M.E. Jamuon (nd)</u>		Date Considered <u>5/9/02 & 7/9/02</u>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					